Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Clinical trial shows leg ulcer benefits of Derma Sciences’ Medihoney wound dressing

Derma Sciences USA : 16 September, 2008  (Company News)
Derma Sciences’ key product, Medihoney Wound and Burn Dressing with Active Leptospermum Honey, has been found in a large randomized controlled clinical trial to improve the healing rates of stalled venous leg ulcers.
Prior to this study, no other advanced wound care dressing, under compression therapy, had been shown to improve healing rates of leg ulcers. Physicians treat over 4 million leg ulcers in the US per year, at a cost exceeding $1 billion.

The trial, a 108-patient randomized and controlled clinical trial, looked at venous leg ulcers that had been proven to be non-healing under standard treatment (compression therapy). In the study, half the patients had a common advanced wound care gel added to the standard treatment, and half had Comvita's Active Leptospermum (Manuka) Honey (now marketed under the brand name Medihoney) added.

After four weeks, the mean reduction in size of the wounds was 34 percent in the honey group and 13 percent in the control group. After 12 weeks, there was a 44 percent complete healing rate in the honey group vs. only 33 percent in the control group. Both these differences were statistically significant.

The findings were published in the Journal of Clinical Nursing, and were written by lead investigators Georgina T Gethin and Seamus Cowman, both of the Royal College of Surgeons in Ireland. They concluded that, 'the [honey] group had shown a greater incidence of healing, more effective desloughing, and lower incidence of infection than the control group.'

Chief executive officer, Ed Quilty stated, 'We are pleased that this important finding has been recognized in such a well-regarded peer reviewed journal serving the global market. Since the product's launch in Europe a couple of years ago, and then the launch in the USA and Canada this year, clinicians have consistently reported that Medihoney is effective on stalled ulcers of various etiologies. The recently published study now provides clear evidence of this by demonstrating results proven in a rigorous randomized controlled study. Clinicians can now feel confident in the value that they place on Medihoney and the role it has to play in an overall treatment strategy”.

“This is significant for our product as currently, only 50 percent of chronic wounds heal with first-line treatment options. It is also significant for patients who suffer the effects of notoriously painful leg ulcers, with uncommonly long durations - sometimes lasting years.'

Wound care is a major healthcare market with an estimated value of $10 billion in 2007 that is expected to grow to $12.5 billion by 2012. The global growth is being driven by several factors, including an aging population, the rise in the global incidence of diabetes and chronic vascular disorders, and a steady advancement in wound care technologies.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo